DK3697405T3 - Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner - Google Patents

Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner Download PDF

Info

Publication number
DK3697405T3
DK3697405T3 DK18800045.9T DK18800045T DK3697405T3 DK 3697405 T3 DK3697405 T3 DK 3697405T3 DK 18800045 T DK18800045 T DK 18800045T DK 3697405 T3 DK3697405 T3 DK 3697405T3
Authority
DK
Denmark
Prior art keywords
viral
treatment
bacterial infections
mek inhibitor
new mek
Prior art date
Application number
DK18800045.9T
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Application granted granted Critical
Publication of DK3697405T3 publication Critical patent/DK3697405T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18800045.9T 2017-10-17 2018-10-17 Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner DK3697405T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
DK3697405T3 true DK3697405T3 (da) 2021-08-23

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18800045.9T DK3697405T3 (da) 2017-10-17 2018-10-17 Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner

Country Status (21)

Country Link
US (1) US11903917B2 (da)
EP (2) EP3697405B1 (da)
JP (2) JP7227967B2 (da)
KR (1) KR20200072499A (da)
CN (1) CN111479566B (da)
AU (1) AU2018351475A1 (da)
BR (1) BR112020007442A2 (da)
CA (1) CA3078424A1 (da)
CY (1) CY1124507T1 (da)
DK (1) DK3697405T3 (da)
EA (1) EA202090693A1 (da)
ES (1) ES2883639T3 (da)
HR (1) HRP20211252T1 (da)
HU (1) HUE055738T2 (da)
LT (1) LT3697405T (da)
MX (2) MX2020003473A (da)
PL (1) PL3697405T3 (da)
PT (1) PT3697405T (da)
SI (1) SI3697405T1 (da)
WO (1) WO2019076947A1 (da)
ZA (1) ZA202002069B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003673A2 (pt) * 2019-08-27 2022-05-24 Atriva Therapeutics Gmbh Combinações de inibidores de mek com inibidores de endonuclease dependente de cap
EP4041212A1 (en) 2019-10-08 2022-08-17 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0104933A3 (en) * 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
TR200200082T2 (tr) * 1999-07-16 2002-04-22 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー N−(4−置換フェニル)−アントラニル酸ヒドロキサメートエステル
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
EP2600862B1 (en) 2010-08-05 2016-04-20 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
US9566281B2 (en) * 2012-10-08 2017-02-14 Atriva Therapeutics Gmbh MEK inhibitors in the treatment of virus diseases
CA2949004A1 (en) 2014-05-16 2015-11-19 Atriva Therapeutics Gmbh Novel anti-infective strategy against influenza virus and s. aureus coinfections
EP4041212A1 (en) 2019-10-08 2022-08-17 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
EP3912623A1 (en) 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
CN111479566A (zh) 2020-07-31
CN111479566B (zh) 2024-05-07
US20200289445A1 (en) 2020-09-17
JP2023058631A (ja) 2023-04-25
HRP20211252T1 (hr) 2021-11-12
SI3697405T1 (sl) 2021-11-30
PL3697405T3 (pl) 2021-12-13
EA202090693A1 (ru) 2020-10-19
WO2019076947A1 (en) 2019-04-25
PT3697405T (pt) 2021-08-27
LT3697405T (lt) 2021-10-25
CA3078424A1 (en) 2019-04-25
ZA202002069B (en) 2021-10-27
MX2022016066A (es) 2023-02-02
KR20200072499A (ko) 2020-06-22
JP2020537659A (ja) 2020-12-24
HUE055738T2 (hu) 2021-12-28
MX2020003473A (es) 2020-10-01
US11903917B2 (en) 2024-02-20
AU2018351475A1 (en) 2020-04-30
BR112020007442A2 (pt) 2020-10-27
EP3973960A1 (en) 2022-03-30
EP3697405B1 (en) 2021-07-14
ES2883639T3 (es) 2021-12-09
JP7227967B2 (ja) 2023-02-22
EP3697405A1 (en) 2020-08-26
CY1124507T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
DK3600364T3 (da) Sammensætninger omfattende en bakteriestamme af slægten megasphaera og anvendelser deraf
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3701973T3 (da) Plasmabaseret film og fremgangsmåder til fremstilling og anvendelse af samme
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3220741T3 (da) Sammensætning og kits til hæmning af patogen mikrobiel infektion og fremgangsmåder til anvendelse af samme
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3607611T3 (da) Kølesystem og fremgangsmåde
DK3641753T3 (da) Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3413897T3 (da) Fremgangsmåder til behandling og profylakse af hiv og aids
DK3759083T3 (da) 2,4-diaminoquinazolinderivater og anvendelse deraf til behandling af virusinfektioner, cancer eller allergier
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3752506T3 (da) Pyrimidinderivater til forebyggelse og behandling af bakterielle infektioner
DK3630143T3 (da) Onkolytisk virus og fremgangsmåde
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi